Relypsa, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$10.1M
Doctors Paid
13,986
Transactions
72,175
2020 Total
$980,819
Payment Breakdown by Category
Research$2.0M (19.9%)
Consulting$1.7M (16.8%)
Food & Beverage$1.6M (15.9%)
Travel$1.1M (10.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.4M | 1,844 | 33.5% |
| Unspecified | $2.0M | 262 | 19.9% |
| Consulting Fee | $1.7M | 491 | 16.8% |
| Food and Beverage | $1.6M | 65,216 | 15.9% |
| Travel and Lodging | $1.1M | 4,022 | 10.4% |
| Grant | $223,651 | 10 | 2.2% |
| Space rental or facility fees (teaching hospital only) | $125,911 | 58 | 1.2% |
| Education | $7,537 | 272 | 0.1% |
Payments by Type
General
$8.1M
71,913 transactions
Research
$2.0M
262 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| AMBER | $457,843 | 0 | 47 |
| IST 7: Rajagopalan (Univ Hosp Cleveland) | $200,628 | 0 | 1 |
| EMERALD | $200,387 | 0 | 37 |
| IST: Bansal - 12 months (Start date: August 2016) | $121,462 | 0 | 3 |
| RLY5016-401 | $119,348 | 0 | 29 |
| IST 5: Edwards (St. Louis University) | $117,217 | 0 | 4 |
| IST 3: Germain-Headley | $100,000 | 0 | 3 |
| Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On (MAGMAAddOn) | $93,627 | 0 | 1 |
| IST 1: Mehta | $76,143 | 0 | 4 |
| HEOR (Intermountain Health Services CHYME Study) | $73,625 | 0 | 2 |
| Association of Potassium Levels with Mortality in Hospitalized Patients | $69,079 | 1 | 2 |
| Emerald | $67,118 | 0 | 74 |
| IST 4: Rafique | $51,149 | 0 | 3 |
| Amber | $48,518 | 0 | 38 |
| Frequency of Cardiac Arrhythmias in Dialysis Patients as a function of Hyperkalemia | $46,867 | 0 | 1 |
| Evaluation of Veltassa (patiromer) to maintain normokalemia in a patient population with chronic ki | $39,160 | 0 | 1 |
| Real World Effectiveness of Patiromer as an Adjunct Therapy in Acute Hyperkalemia | $30,525 | 0 | 2 |
| IST: Bansal - 12 months (Start date: August 2016) (PI MDM ID: 100032946) | $23,596 | 0 | 1 |
| Frequency of Cardiac Arrhythmias in Dialysis Patients as a | $23,443 | 0 | 1 |
| Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney | $22,458 | 0 | 1 |
| IST: Rogosin - Dr. Jun Lee | $22,458 | 0 | 1 |
| RLY5016-206p_IRB Fees_Site 1111_Butani_Corrected | $5,000 | 0 | 2 |
| Pharmacokinetic study of tacrolimus and mycophenolate mofetil in kidney transplant recipients | $3,430 | 0 | 2 |
| Comparison of Patiromer with Sodium Polystyrene (Kayexalate) in their ability | $2,000 | 0 | 1 |
| CHYME Study | $1,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Rajiv Agarwal, M.d, M.D | Nephrology | Indianapolis, IN | $56,915 | $0 |
| Dr. Harry Dounis, Do, DO | Nephrology | Neptune, NJ | $52,990 | $0 |
| Robert Mohapatra, Md, Mph, MD, MPH | Advanced Heart Failure and Transplant Cardiology | Sewell, NJ | $51,667 | $0 |
| Ellie Kelepouris, Md, MD | Nephrology | Philadelphia, PA | $50,596 | $0 |
| Unknown Provider | — | — | $50,378 | $0 |
| Dr. Jones Samuel, Md, MD | Nephrology | Baton Rouge, LA | $49,446 | $0 |
| Dr. Uri Elkayam, M.d, M.D | Cardiovascular Disease | Los Angeles, CA | $49,286 | $0 |
| Lawrence Byrd, M.d, M.D | Nephrology | Livingston, NJ | $48,084 | $0 |
| Dr. Allen Anderson, Md, MD | Internal Medicine | San Antonio, TX | $47,547 | $0 |
| Dr. Saravanan Balamuthusamy, M.d, M.D | Internal Medicine | Fort Worth, TX | $47,133 | $0 |
| Abdul Abdellatif, M.d, M.D | Internal Medicine | Webster, TX | $46,828 | $0 |
| Dr. Subir Paul, M.d, M.D | Internal Medicine | Florence, AL | $44,448 | $0 |
| Dr. Matthew Weir, M.d, M.D | Nephrology | Baltimore, MD | $43,983 | $0 |
| Anand Saranathan, M.d, M.D | Specialist | Houston, TX | $43,562 | $0 |
| Mr. Deep Patel, Md, MD | Nephrology | Mechanicsville, VA | $42,496 | $0 |
| Charles Herzog, Md, MD | Cardiovascular Disease | Minneapolis, MN | $42,296 | $0 |
| Jonathan Winston, Md, MD | Nephrology | New York, NY | $42,257 | $0 |
| Phillip Madonia, M.d, M.D | Nephrology | Alabaster, AL | $42,166 | $0 |
| Dr. Parin Makadia, Md, MD | Student in an Organized Health Care Education/Training Program | Desoto, TX | $41,139 | $0 |
| Unknown Provider | — | — | $41,138 | $0 |
| Paul Hauptman, Md, MD | Cardiovascular Disease | St Louis, MO | $40,903 | $0 |
| Harry Goss, Md, MD | Nephrology | Austin, TX | $39,989 | $0 |
| Luis Garcia-Mayol, Md, MD | Nephrology | Coral Gables, FL | $39,199 | $0 |
| Dr. George Osuchukwu, M.d, M.D | Nephrology | Victoria, TX | $38,472 | $0 |
| Khaled Nashar, Md, MD | Nephrology | Pittsburgh, PA | $38,331 | $0 |
About Relypsa, Inc.
Relypsa, Inc. has made $10.1M in payments to 13,986 healthcare providers, recorded across 72,175 transactions in the CMS Open Payments database. In 2020, the company paid $980,819. The top product by payment volume is Veltassa ($8.2M).
Payments were distributed across 133 medical specialties. The top specialty by payment amount is Nephrology ($4.1M to 3,856 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($1.7M), Research ($2.0M), Travel & Lodging ($1.1M).
Relypsa, Inc. is associated with 1 products in the CMS Open Payments database.